(NASDAQ: APVO) Aptevo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Aptevo Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast APVO's revenue for 2026 to be $10,061,131, with the lowest APVO revenue forecast at $10,061,131, and the highest APVO revenue forecast at $10,061,131. On average, 1 Wall Street analysts forecast APVO's revenue for 2027 to be $30,908,904, with the lowest APVO revenue forecast at $30,908,904, and the highest APVO revenue forecast at $30,908,904.
In 2028, APVO is forecast to generate $41,151,413 in revenue, with the lowest revenue forecast at $41,151,413 and the highest revenue forecast at $41,151,413.